2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1064

Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Abstract Number: 1065

Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway
Abstract Number: 1066

Invention and Phenotypic Evaluation of Human IgG4-Knock-in Mice
Abstract Number: 1067

Clinical Significance of Anti-Dense Fine Speckled 70 and Dense Fine Speckled Pattern in Diagnosis of Systemic Autoimmune Rheumatic Disease
Abstract Number: 1068

Impact of TNF Antagonist Treatment on the Gut Microbiome In Vivo
Abstract Number: 1069

Significantly Elevated Serum Protein-Adduction with 4-Hydroxy-2-Nonenal but Not Malondialdehyde in Sjogren’s Syndrome
Abstract Number: 1070

Phenotypic Characterization of Peripheral Basophil Perturbations in the Antiphospholipid Syndrome
Abstract Number: 1071

Increased Susceptibility of SLE-Prone Mice to Pulmonary Haemophilus Influenzae Infection Was Attributed to Dysfunctions of Innate Immune Responses
Abstract Number: 1072

Mutated Peptidylarginine Deiminase from Porphyromonas Gingivalis Is a Target in Rheumatoid Arthritis and Citrullinates Major RA-Autoantigens
Abstract Number: 1073

Aberrant Cell Signaling in Peripheral Blood Mononuclear Cells upon Interferon Alpha Stimulation in Patients with Primary Sjögren’s Syndrome Associates with Type I Interferon Signature
Abstract Number: 1074

High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis
Abstract Number: 1075

Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor and Cytotoxic Potential of NK Cells in Patients with Behcet Disease
Abstract Number: 1076

TGF-β1 Induces AXL in Murine and Human Synovium and Protects Ankle Joints, but Not Knee Joints, during Murine Inflammatory Arthritis
Abstract Number: 1077

The Lectin Pathway of the Complement System Is Activated in Patients with Systemic Lupus Erythematosus
Abstract Number: 1078

Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].